These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

657 related articles for article (PubMed ID: 18618965)

  • 1. Losing deference in the FDA's second century: judicial review, politics, and a diminished legacy of expertise.
    O'Reilly JT
    Cornell Law Rev; 2008 Jul; 93(5):939-80. PubMed ID: 18618965
    [No Abstract]   [Full Text] [Related]  

  • 2. The FDA and deference lost: a self-inflicted wound or the product of a wounded agency? A response to Professor O'Reilly.
    Vladeck DC
    Cornell Law Rev; 2008 Jul; 93(5):981-1002. PubMed ID: 18618967
    [No Abstract]   [Full Text] [Related]  

  • 3. The FDA, preemption, and the Supreme Court.
    Glantz LH; Annas GJ
    N Engl J Med; 2008 May; 358(18):1883-5. PubMed ID: 18450601
    [No Abstract]   [Full Text] [Related]  

  • 4. The history and contemporary challenges of the US Food and Drug Administration.
    Borchers AT; Hagie F; Keen CL; Gershwin ME
    Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The need for federal preemption of state tort claims in the context of "new drugs" and premarket-approved medical devices.
    Mottes LM
    Seton Hall Law Rev; 2011; 41(2):723-63. PubMed ID: 21739761
    [No Abstract]   [Full Text] [Related]  

  • 6. Access before approval--a right to take experimental drugs?
    Okie S
    N Engl J Med; 2006 Aug; 355(5):437-40. PubMed ID: 16885545
    [No Abstract]   [Full Text] [Related]  

  • 7. Good law from tragic facts--Congress, the FDA, and preemption.
    Annas GJ
    N Engl J Med; 2009 Sep; 361(12):1206-11. PubMed ID: 19759383
    [No Abstract]   [Full Text] [Related]  

  • 8. The Supreme Court's abortion decisions: some observations on the exercise of judicial review in the United States.
    Grossman JB
    Sven Juristtidn; 1973; 58(6-7):449-62. PubMed ID: 11663642
    [No Abstract]   [Full Text] [Related]  

  • 9. Tobacco, public health, and the FDA.
    Curfman GD; Morrissey S; Drazen JM
    N Engl J Med; 2009 Jul; 361(4):402-3. PubMed ID: 19546344
    [No Abstract]   [Full Text] [Related]  

  • 10. Shifting terrain in the regulation of off-label promotion of pharmaceuticals.
    Mello MM; Studdert DM; Brennan TA
    N Engl J Med; 2009 Apr; 360(15):1557-66. PubMed ID: 19357413
    [No Abstract]   [Full Text] [Related]  

  • 11. The new Food and Drug Administration drug package insert: implications for patient safety and clinical care.
    Watson KT; Barash PG
    Anesth Analg; 2009 Jan; 108(1):211-8. PubMed ID: 19095852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Teaching clinicians about drugs--50 years later, whose job is it?
    Avorn J
    N Engl J Med; 2011 Mar; 364(13):1185-7. PubMed ID: 21449781
    [No Abstract]   [Full Text] [Related]  

  • 13. Science and regulation. FDA's approach to regulation of products of nanotechnology.
    Hamburg MA
    Science; 2012 Apr; 336(6079):299-300. PubMed ID: 22517845
    [No Abstract]   [Full Text] [Related]  

  • 14. Tobacco control and free speech--an American dilemma.
    Bayer R; Kelly M
    N Engl J Med; 2010 Jan; 362(4):281-3. PubMed ID: 20071696
    [No Abstract]   [Full Text] [Related]  

  • 15. The FDA Amendments Act of 2007 - Assessing Its Effects a Decade Later.
    Avorn J; Kesselheim A; Sarpatwari A
    N Engl J Med; 2018 Sep; 379(12):1097-1099. PubMed ID: 30231220
    [No Abstract]   [Full Text] [Related]  

  • 16. The Prescription Drug User Fee Act: is a faster Food and Drug Administration always a better Food and Drug Administration?
    Zelenay JL
    Food Drug Law J; 2005; 60(2):261-338. PubMed ID: 16094773
    [No Abstract]   [Full Text] [Related]  

  • 17. Drug review "behind the curtain": a response to Professor Struve.
    O'Reilly JT
    Cornell Law Rev; 2008 Jul; 93(5):1075-90. PubMed ID: 18618971
    [No Abstract]   [Full Text] [Related]  

  • 18. The Supreme Court's Abortion Exceptionalism - Judicial Deference, Medical Science, and Mifepristone Access.
    Fox D; Cole E
    N Engl J Med; 2021 Jun; 384(24):e94. PubMed ID: 33909959
    [No Abstract]   [Full Text] [Related]  

  • 19. The challenges of globalization in pharmaceutical law--is an international drug approval system modeled after the European system worth considering?
    Purnhagen KP
    Food Drug Law J; 2008; 63(3):623-45. PubMed ID: 19031663
    [No Abstract]   [Full Text] [Related]  

  • 20. The right to a trial: Should dying patients have access to experimental drugs?
    Groopman J
    New Yorker; 2006 Dec; ():40-7. PubMed ID: 17176539
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 33.